Switch to:
More From Other Websites
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration May 30 2017
Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo... May 30 2017
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb May 28 2017
CORRECTING and REPLACING Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO... May 26 2017
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer May 26 2017
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data May 26 2017
Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017 May 26 2017
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer May 25 2017
Getting Struck Twice: Acquisitions And Spinouts In Biotech May 25 2017
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application... May 24 2017
Performance of Merck’s Diabetes Portfolio in 1Q17 May 24 2017
With Stock Returns Of Over 205% in the Last Year, This Fund Is Proof That Hedge Funds Aren’t Going... May 23 2017
Blog Coverage: Bristol-Myers Squibs Received EMA Validation of Sprycel for the Treatment in Children... May 22 2017
What Orencia Meant to BMY in 1Q17 May 22 2017
New Research Reports for Britol-Myers, Pricline & Phillips 66 May 19 2017
Behind BMY’s Cardiovascular Performance in 1Q17 May 19 2017
Revisiting Bristol-Myers Squibb’s Virology in 1Q17 May 19 2017
European Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in... May 19 2017
What Happened to Bristol-Myers Squibb’s Opdivo in 1Q17? May 19 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK